Orchestra BioMed Holdings, Inc.

OBIO

US68572M1062

Advanced Medical Equipment & Technology

Real-time Estimate Cboe BZX Other stock markets 12:45:33 2024-07-16 EDT			5-day change	1st Jan Change
8.265 ^USD	-3.11%		+3.87%	-8.87%

07-01	Orchestra BioMed Holdings, Inc.(NasdaqGM:OBIO) added to Russell Small Cap Comp Value Index	CI
07-01	Orchestra BioMed Holdings, Inc.(NasdaqGM:OBIO) added to Russell 3000 Value Index	CI

Orchestra BioMed Holdings, Inc.(NasdaqGM:OBIO) added to Russell Microcap Value Index

July 30, 2024

Latest news about Orchestra BioMed Holdings, Inc.

Orchestra BioMed Holdings, Inc.(NasdaqGM:OBIO) added to Russell Small Cap Comp Value Index	06-30	CI
Orchestra BioMed Holdings, Inc.(NasdaqGM:OBIO) added to Russell 3000 Value Index	06-30	CI
Orchestra BioMed Holdings, Inc.(NasdaqGM:OBIO) added to Russell 2500 Value Index	06-30	CI
Orchestra BioMed Holdings, Inc.(NasdaqGM:OBIO) added to Russell 2000 Value Index	06-30	CI
Orchestra BioMed Holdings, Inc.(NasdaqGM:OBIO) added to Russell Microcap Value Index	06-30	CI
Orchestra BioMed Holdings, Inc.(NasdaqGM:OBIO) added to Russell 3000E Value Index	06-30	CI
Earnings Flash (OBIO) ORCHESTRA BIOMED HOLDINGS Reports Q1 Revenue $620,000	05-13	MT
Orchestra BioMed Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-13	CI
Orchestra BioMed Holdings, Inc. Announces AVIM Therapy Global Intellectual Property Estate Reaches 110 Issued Patents	04-30	CI
Orchestra BioMed Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-27	CI
Orchestra BioMed Holdings, Inc. Announces Appointment of David Pacitti to Board of Directors	03-26	CI
Orchestra Biomed Holdings, Inc. Demonstrates Strength of Cardiovascular Pipeline with Virtue SAB and AVIM Therapy Presentations at CRT 2024 Annual Meeting	03-13	CI
Orchestra Biomed Holdings, Inc. Announces Presentation of Results from Clinical Study Demonstrating Favorable Hemodynamic Effects of AVIM Therapy in Hypertensive Pacemaker Patients	03-06	CI
Orchestra Biomed Presents New Data Showing Sustained Clinically Meaningful Reduction in 24-Hour Ambulatory Systolic Blood Pressure in Hypertensive Pacemaker Patients Treated with Avim Therapy for over 3 Years	02-26	CI
Jefferies Initiates Orchestra BioMed With Buy Rating, Price Target is $14	01-19	MT
Orchestra Biomed Announces Initiation of Backbeat Pivotal Study of Avim Therapy in Hypertensive Pacemaker Patients	01-08	CI
Earnings Flash (OBIO) ORCHESTRA BIOMED HOLDINGS Reports Q3 Revenue $419,000	11-13	MT
Sector Update: Health Care Stocks Steady Late Afternoon	23-09-19	MT
Sector Update: Health Care Stocks Lower Tuesday Afternoon	23-09-19	MT
Sector Update: Health Care	23-09-19	MT
Orchestra BioMed Gets FDA Approval to Begin Study of BackBeat CNT for Hypertension in Pacemaker Patients; Shares Jump	23-09-19	MT
Orchestra BioMed Shares Jump on FDA Nod for BackBeat Study	23-09-19	DJ
Orchestra BioMed Gets FDA Nod for BackBeat Study	23-09-19	DJ
Earnings Flash (OBIO) ORCHESTRA BIOMED HOLDINGS Reports Q2 Revenue $915,000	23-08-10	MT
Orchestra Biomed Holdings, Inc. Receives Fda Approval of Ide for U.S. Pivotal Study of Virtue(R) Sirolimus Angioinfusion Balloon in Patients with Coronary In-Stent Restenosis	23-08-08	CI

Chart Orchestra BioMed Holdings, Inc.

Duration

Period

More charts

Orchestra BioMed Holdings, Inc. is a biomedical innovation company. Its lead product candidate is BackBeat Cardiac Neuromodulation Therapy (BackBeat CNT) for the treatment of hypertension (HTN), the leading risk factor for death worldwide. It is also developing the Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. It is developing bioelectronic therapies based on patented CNT technology. BackBeat CNT, also known as Atrioventricular Interval Modulation (AVIM) therapy, is a bioelectronic therapy candidate designed to substantially and persistently lower blood pressure. Virtue SAB is a proprietary drug/device combination product candidate for the treatment of artery disease that is designed to deliver a proprietary, investigational, extended-release formulation of sirolimus (SirolimusEFR) to the vessel wall during balloon angioplasty without the need for balloon coating or a permanent implant.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-08-07 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Orchestra BioMed Holdings, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

8.53 USD

Average target price

16.33 USD

Spread / Average Target

+91.48%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
ORCHESTRA BIOMED HOLDINGS, INC.	-8.87%	305M
THERMO FISHER SCIENTIFIC	+3.90%	208B
DANAHER CORPORATION	+8.05%	182B
INTUITIVE SURGICAL, INC.	+29.01%	155B
BOSTON SCIENTIFIC CORPORATION	+34.96%	115B
SIEMENS HEALTHINEERS AG	+2.55%	66.52B
EDWARDS LIFESCIENCES CORPORATION	+14.62%	53.93B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	-6.47%	46.26B
AGILENT TECHNOLOGIES, INC.	-2.81%	38.22B
GE HEALTHCARE TECHNOLOGIES INC.	+6.36%	36.6B

Other Advanced Medical Equipment & Technology